Temelimab (previously known as GNbAC1) is an immunoglobulin (Ig) G4 monoclonal antibody against the human endogenous retroviral envelope protein HERV-W-Env that has been shown to be associated with the pathogenesis of certain autoimmune diseases, such as multiple sclerosis (MS) and type 1 diabetes mellitus (T1D).